Usefulness of Statin-Ezetimibe Combination to Reduce the Care Gap in Dyslipidemia Management in Patients With a High Risk of Atherosclerotic Disease

American Journal of Cardiology

Volumn 104, Issue 6, 2009, Pages

  Teoh, Hwee ^a   Mendelsohn, Aurora A ^b   Goodman, Shaun G ^a,b   Jaffer, Shahin ^d   Chen, Richard Y Y ^c   Tjia, Sabine ^e   Theriault, Lyne ^f   Langer, Anatoly ^a,b   Leiter, Lawrence A ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b CANADIAN HEART RESEARCH CENTRE   (Canada)

^c Kingsbridge Medical Centre   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e Clinique Lasalle Medicale   (Canada)

^f Clin Familiale des Boies Francs and Hôtel Dieu d'Arthabaska   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DRUG DOSE TITRATION; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPEN STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 69649104555     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.05.019     Document Type: Article

References (25)

1. Pearson T.A., Laurora I., Chu H., and Kafonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 160 (2000) 459-467
2. Hackam D.G., Leiter L.A., Yan A.T., Yan R.T., Mendelsohn A., Tan M., Zavodni L., Chen R., Tsang J.L., Kundi A., Lin P.J., Fitchett D.H., Langer A., and Goodman S.G. Missed opportunities for the secondary prevention of cardiovascular disease in Canada. Can J Cardiol 23 (2007) 1124-1130
3. Yan A.T., Yan R.T., Tan M., Hackam D.G., Leblanc K.L., Kertland H., Tsang J.L., Jaffer S., Kates M.L., Leiter L.A., Fitchett D.H., Langer A., and Goodman S.G. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 119 (2006) 676-683
4. Banegas J.R., Vegazo O., Serrano P., Luengo E., Mantilla T., Fernandez R., and Civeira F. The gap between dyslipidemia control perceived by physicians and objective control patterns in Spain. Atherosclerosis 188 (2006) 420-424
5. Ko D.T., Mamdani M., and Alter D.A. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 291 (2004) 1864-1870
6. Petrella R.J., Merikle E., and Jones J. Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis. Clin Ther 29 (2007) 742-750
7. Davidson M.H., McGarry T., Bettis R., Melani L., Lipka L.J., LeBeaut A.P., Suresh R., Sun S., and Veltri E.P. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 40 (2002) 2125-2134
8. Pedersen T.R., Faergeman O., Kastelein J.J., Olsson A.G., Tikkanen M.J., Holme I., Larsen M.L., Bendiksen F.S., Lindahl C., Szarek M., and Tsai J. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294 (2005) 2437-2445
9. Ballantyne C.M., Weiss R., Moccetti T., Vogt A., Eber B., Sosef F., and Duffield E. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 99 (2007) 673-680
10. Kerzner B., Corbelli J., Sharp S., Lipka L.J., Melani L., LeBeaut A., Suresh R., Mukhopadhyay P., and Veltri E.P. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 91 (2003) 418-424
11. Melani L., Mills R., Hassman D., Lipetz R., Lipka L., LeBeaut A., Suresh R., Mukhopadhyay P., and Veltri E. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 24 (2003) 717-728
12. Patel J.V., and Hughes E.A. Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia. Int J Clin Pract 60 (2006) 914-921
13. McPherson R., Frohlich J., Fodor G., Genest J., and Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement-recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 22 (2006) 913-927
14. Genest J., Frohlich J., Fodor G., and McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 169 (2003) 921-924
15. Jones P.H., McKenney J.M., Karalis D.G., and Downey J. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Am Heart J 149 (2005) e1-e8
16. Martineau P., Gaw A., de Teresa E., Farsang C., Gensini G.F., Leiter L.A., and Langer A. Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study. Atherosclerosis 191 (2007) 135-146
17. Jackevicius C.A., Tu J.V., Ross J.S., Ko D.T., and Krumholz H.M. Use of ezetimibe in the United States and Canada. N Engl J Med 358 (2008) 1819-1828
18. Leiter L.A., Betteridge D.J., Chacra A.R., Chait A., Ferrannini E., Haffner S.M., Kadowaki T., Tuomilehto J., Zimmet P., Newman C.B., Hey-Hadavi J., and Walkinshaw C. AUDIT study. Evidence of global undertreatment of dyslipidaemia in patients with type 2 diabetes mellitus. Br J Diabetes Vasc Dis 6 (2006) 31-40
19. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts), Graham I., Atar D., Borch-Johnsen K., Boysen G., Burell G., Cifkova R., Dallongeville J., De Backer G., Ebrahim S., Gjelsvik B., Herrmann-Lingen C., Hoes A., Humphries S., Knapton M., Perk J., Priori S.G., Pyorala K., Reiner Z., Ruilope L., Sans-Menendez S., Op Reimer W.S., Weissberg P., Wood D., Yarnell J., Zamorano J.L., Walma E., Fitzgerald T., Cooney M.T., Dudina A., Vahanian A., Camm J., De Caterina R., Dean V., Dickstein K., Funck-Brentano C., Filippatos G., Hellemans I., Kristensen S.D., McGregor K., Sechtem U., Silber S., Tendera M., Widimsky P., Altiner A., Bonora E., Durrington P.N., Fagard R., Giampaoli S., Hemingway H., Hakansson J., Kjeldsen S.E., Larsen L., Mancia G., Manolis A.J., Orth-Gomer K., Pedersen T., Rayner M., Ryden L., Sammut M., Schneiderman N., Stalenhoef A.F., Tokgozoglu L., Wiklund O., and Zampelas A. European guidelines on cardiovascular disease prevention in clinical practice: full text. Eur J Cardiovasc Prev Rehabil 14 suppl 2 (2007) S1-S113
20. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts), Graham I., Atar D., Borch-Johnsen K., Boysen G., Burell G., Cifkova R., Dallongeville J., De Backer G., Ebrahim S., Gjelsvik B., Herrmann-Lingen C., Hoes A., Humphries S., Knapton M., Perk J., Priori S.G., Pyorala K., Reiner Z., Ruilope L., Sans-Menendez S., Op Reimer W.S., Weissberg P., Wood D., Yarnell J., Zamorano J.L., Walma E., Fitzgerald T., Cooney M.T., Dudina A., Vahanian A., Camm J., De Caterina R., Dean V., Dickstein K., Funck-Brentano C., Filippatos G., Hellemans I., Kristensen S.D., McGregor K., Sechtem U., Silber S., Tendera M., Widimsky P., Altiner A., Bonora E., Durrington P.N., Fagard R., Giampaoli S., Hemingway H., Hakansson J., Kjeldsen S.E., Larsen M.L., Mancia G., Manolis A.J., Orth-Gomer K., Pedersen T., Rayner M., Ryden L., Sammut M., Schneiderman N., Stalenhoef A.F., Tokgozoglu L., Wiklund O., and Zampelas A. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur J Cardiovasc Prev Rehabil 14 suppl 2 (2007) E1-E40
21. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., and Stone N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 44 (2004) 720-732
22. Rodondi N., Peng T., Karter A.J., Bauer D.C., Vittinghoff E., Tang S., Pettitt D., Kerr E.A., and Selby J.V. Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann Intern Med 144 (2006) 475-484
23. Bruckert E., Giral P., and Tellier P. Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation 107 (2003) 3124-3128
24. Pearson T.A., Denke M.A., McBride P.E., Battisti W.P., Brady W.E., and Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 80 (2005) 587-595
25. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., Kirby A., Sourjina T., Peto R., Collins R., and Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278